A critical assessment of post-prostatectomy prostate specific antigen doubling time acceleration - Is it stable?

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: We examined a retrospective cohort of patients with biochemical recurrence after prostatectomy to determine whether prostate specific antigen doubling time would remain stable with time. We also examined the relationship between other clinical parameters and the change in prostate specific antigen doubling time. Materials and Methods: We retrospectively reviewed the prostate cancer database from 1989 to 2008 to identify patients treated with radical prostatectomy for prostate cancer who experienced prostate specific antigen recurrence. Of the 2,237 patients identified 329 had biochemical recurrence. Prostate specific antigen doubling time was calculated at each visit and linear regression of prostate specific antigen doubling time with time was fit. Rate of change in prostate specific antigen doubling time was defined as the slope of the least squares regression line. Results: Median followup was 5 years (range 0.2 to 18). High Gleason score and local recurrence within 5 years were significantly associated with shorter 2-year prostate specific antigen doubling time and a decreased rate of change in doubling time (p = 0.0096, 0.0119, 0.0195 and 0.0258, respectively). Metastasis within 5 years was significantly associated with shorter 2 and 5-year doubling time (p = 0.0006 and 0.0014, respectively). Using all prostate specific antigen values within 5 years of initial biochemical recurrence yielded an overall median prostate specific antigen doubling time of 52.8 months (range 5.4 to 100.0). The median rate of change in doubling time was -1.05 (range -64.7 to 27.0). Median time to metastasis after biochemical recurrence was 12.9 years. Conclusions: Median prostate specific antigen doubling time decreases with time. This may influence the decision to offer secondary therapy to patients with biochemical recurrence sooner since initial prostate specific antigen doubling time is long and may not accurately reflect the biological nature of the disease.

Original languageEnglish
Pages (from-to)1614-1619
Number of pages6
JournalJournal of Urology
Volume187
Issue number5
DOIs
StatePublished - May 2012

Fingerprint

Prostate-Specific Antigen
Prostatectomy
Recurrence
Prostatic Neoplasms
Neoplasm Metastasis
Neoplasm Grading
Least-Squares Analysis
Linear Models

Keywords

  • carcinoma
  • neoplasm metastasis
  • prostate
  • prostate-specific antigen
  • prostatectomy

ASJC Scopus subject areas

  • Urology

Cite this

A critical assessment of post-prostatectomy prostate specific antigen doubling time acceleration - Is it stable? / Cary, K. Clinton; Johnson, Cynthia S.; Cheng, Liang; Koch, Michael.

In: Journal of Urology, Vol. 187, No. 5, 05.2012, p. 1614-1619.

Research output: Contribution to journalArticle

@article{781271f081ae4ddab475663c22144bf9,
title = "A critical assessment of post-prostatectomy prostate specific antigen doubling time acceleration - Is it stable?",
abstract = "Purpose: We examined a retrospective cohort of patients with biochemical recurrence after prostatectomy to determine whether prostate specific antigen doubling time would remain stable with time. We also examined the relationship between other clinical parameters and the change in prostate specific antigen doubling time. Materials and Methods: We retrospectively reviewed the prostate cancer database from 1989 to 2008 to identify patients treated with radical prostatectomy for prostate cancer who experienced prostate specific antigen recurrence. Of the 2,237 patients identified 329 had biochemical recurrence. Prostate specific antigen doubling time was calculated at each visit and linear regression of prostate specific antigen doubling time with time was fit. Rate of change in prostate specific antigen doubling time was defined as the slope of the least squares regression line. Results: Median followup was 5 years (range 0.2 to 18). High Gleason score and local recurrence within 5 years were significantly associated with shorter 2-year prostate specific antigen doubling time and a decreased rate of change in doubling time (p = 0.0096, 0.0119, 0.0195 and 0.0258, respectively). Metastasis within 5 years was significantly associated with shorter 2 and 5-year doubling time (p = 0.0006 and 0.0014, respectively). Using all prostate specific antigen values within 5 years of initial biochemical recurrence yielded an overall median prostate specific antigen doubling time of 52.8 months (range 5.4 to 100.0). The median rate of change in doubling time was -1.05 (range -64.7 to 27.0). Median time to metastasis after biochemical recurrence was 12.9 years. Conclusions: Median prostate specific antigen doubling time decreases with time. This may influence the decision to offer secondary therapy to patients with biochemical recurrence sooner since initial prostate specific antigen doubling time is long and may not accurately reflect the biological nature of the disease.",
keywords = "carcinoma, neoplasm metastasis, prostate, prostate-specific antigen, prostatectomy",
author = "Cary, {K. Clinton} and Johnson, {Cynthia S.} and Liang Cheng and Michael Koch",
year = "2012",
month = "5",
doi = "10.1016/j.juro.2011.12.069",
language = "English",
volume = "187",
pages = "1614--1619",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - A critical assessment of post-prostatectomy prostate specific antigen doubling time acceleration - Is it stable?

AU - Cary, K. Clinton

AU - Johnson, Cynthia S.

AU - Cheng, Liang

AU - Koch, Michael

PY - 2012/5

Y1 - 2012/5

N2 - Purpose: We examined a retrospective cohort of patients with biochemical recurrence after prostatectomy to determine whether prostate specific antigen doubling time would remain stable with time. We also examined the relationship between other clinical parameters and the change in prostate specific antigen doubling time. Materials and Methods: We retrospectively reviewed the prostate cancer database from 1989 to 2008 to identify patients treated with radical prostatectomy for prostate cancer who experienced prostate specific antigen recurrence. Of the 2,237 patients identified 329 had biochemical recurrence. Prostate specific antigen doubling time was calculated at each visit and linear regression of prostate specific antigen doubling time with time was fit. Rate of change in prostate specific antigen doubling time was defined as the slope of the least squares regression line. Results: Median followup was 5 years (range 0.2 to 18). High Gleason score and local recurrence within 5 years were significantly associated with shorter 2-year prostate specific antigen doubling time and a decreased rate of change in doubling time (p = 0.0096, 0.0119, 0.0195 and 0.0258, respectively). Metastasis within 5 years was significantly associated with shorter 2 and 5-year doubling time (p = 0.0006 and 0.0014, respectively). Using all prostate specific antigen values within 5 years of initial biochemical recurrence yielded an overall median prostate specific antigen doubling time of 52.8 months (range 5.4 to 100.0). The median rate of change in doubling time was -1.05 (range -64.7 to 27.0). Median time to metastasis after biochemical recurrence was 12.9 years. Conclusions: Median prostate specific antigen doubling time decreases with time. This may influence the decision to offer secondary therapy to patients with biochemical recurrence sooner since initial prostate specific antigen doubling time is long and may not accurately reflect the biological nature of the disease.

AB - Purpose: We examined a retrospective cohort of patients with biochemical recurrence after prostatectomy to determine whether prostate specific antigen doubling time would remain stable with time. We also examined the relationship between other clinical parameters and the change in prostate specific antigen doubling time. Materials and Methods: We retrospectively reviewed the prostate cancer database from 1989 to 2008 to identify patients treated with radical prostatectomy for prostate cancer who experienced prostate specific antigen recurrence. Of the 2,237 patients identified 329 had biochemical recurrence. Prostate specific antigen doubling time was calculated at each visit and linear regression of prostate specific antigen doubling time with time was fit. Rate of change in prostate specific antigen doubling time was defined as the slope of the least squares regression line. Results: Median followup was 5 years (range 0.2 to 18). High Gleason score and local recurrence within 5 years were significantly associated with shorter 2-year prostate specific antigen doubling time and a decreased rate of change in doubling time (p = 0.0096, 0.0119, 0.0195 and 0.0258, respectively). Metastasis within 5 years was significantly associated with shorter 2 and 5-year doubling time (p = 0.0006 and 0.0014, respectively). Using all prostate specific antigen values within 5 years of initial biochemical recurrence yielded an overall median prostate specific antigen doubling time of 52.8 months (range 5.4 to 100.0). The median rate of change in doubling time was -1.05 (range -64.7 to 27.0). Median time to metastasis after biochemical recurrence was 12.9 years. Conclusions: Median prostate specific antigen doubling time decreases with time. This may influence the decision to offer secondary therapy to patients with biochemical recurrence sooner since initial prostate specific antigen doubling time is long and may not accurately reflect the biological nature of the disease.

KW - carcinoma

KW - neoplasm metastasis

KW - prostate

KW - prostate-specific antigen

KW - prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=84863394560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863394560&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2011.12.069

DO - 10.1016/j.juro.2011.12.069

M3 - Article

C2 - 22425101

AN - SCOPUS:84863394560

VL - 187

SP - 1614

EP - 1619

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -